The present invention provides a human nasopharyngeal carcinoma cell line derived from a patient derived xenograft. The novel human nasopharyngeal carcinoma cells comprise human herpesvirus 4 and specific short tandem repeat loci. Also provided are cellular composition comprising the novel nasopharyngeal carcinoma cell line described herein and the use of the novel nasopharyngeal carcinoma cell line for detecting a potential therapeutic agent.

The invention provides methods of preparing a sample of viable diseased cells obtained from a human subject for clinical testing, wherein the methods inhibit anoikis and/or anoikis in the cells while maintaining the physiological functions and genomic composition of the cells when they were in vivo. In the methods of the invention, primary cells are cultured in media comprising at least one anoikis inhibitor, preferably at least one inhibitor of an intrinsic anoikis pathway and at least one inhibitor of an extrinsic anoikis pathway, under anti-anoikis atmospheric conditions, such as greater than 2% and less than 20% oxygen. Method combining multiple culturing conditions, including surface attachment under conditions that inhibit anoikis, are also provided. Compositions and kits for use in the methods of the invention are also provided.

Certain universal neoepitopes and cancer specific neoepitopes and methods therefore are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

The present invention relates to a chemically defined medium for eukaryotic cell culture, comprising water, at least one carbon source, one or more vitamins, one or more salts, one or more growth factors, one or more fatty acids, one or more buffer components, selenium and one or more further trace elements and its use in the culture of cancer stem cells, in particular tumorsphere culture of cancer stem cells.

The present application discloses a method for generating less mature cells from starting cells including inducing the starting cells to revert to a less mature state including increasing the amount of an NME family member whose multimerization state is the biologically active state or decreasing the relative amount of an NME family member whose multimerization state is the biologically inactive state.

The present invention relates to an indirect three-dimensional co-culture. The indirect co-culture may comprise bone marrow niche cells, tumor cells and a culture medium. The bone marrow niche cells and the tumor cells may be incubated in the culture medium without direct contact between the bone marrow niche cells and the tumor cells. The tumor cells may be dormant or reactivated. Also provided are a method for preparing the indirect co-culture and a method for screening for an agent capable of inhibiting reactivation of dormant tumor cells or promoting dormancy of proliferating tumor cells.

The present invention discloses a method for establishing a colorectal cancer HK2 reporter gene cell line, specifically including: firstly, designing a site-specific sgRNA sequence of an HK2 gene, and cloning same into a PX459 plasmid; integrating a homologous recombination sequence of an HK2 gene and a green fluorescent protein DNA fragment (EGFP), and transforming the plasmid and the integrated fragment together into a colorectal cancer cell line HCT116 by electroporation; and performing signal cell screening through a flow cytometer to obtain EGFP-expressing cells, and amplifying a monoclonal cell line; and identifying a positive HK2 reporter gene cell line through PCR identification and Western blot, among screened EGFP-expressing cell lines. The colorectal cancer cell line HK2 gene and EGFP are co-expressed, and the expression level of the EGFP is highly consistent with that of the HK2 gene. Therefore, the expression level of the HK2 gene can be accurately determined by detecting a change in the expression level of the EGFP. The method for establishing a cell line in the present invention are simple, easy to implement and efficient, and a gene site can be precisely positioned.

The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).

An ex vivo tissue composition comprising an isolated tissue explant and tissue graft is provided. Methods of making and using the tissue composition are also provided.